A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium
Pediatric Blood & Cancer2013Vol. 60(11), pp. 1868–1874
Citations Over TimeTop 13% of 2013 papers
Alexandra P. Zorzi, Mark L. Bernstein, Yvan Samson, Donna A. Wall, Sunil Desai, Darcy Nicksy, Nancy Wainman, Elizabeth A. Eisenhauer, Sylvain Baruchel
Abstract
Pracinostat is reasonably well tolerated in children with refractory solid tumors. The RP2D is 45 mg/m(2) .
Related Papers
- → Similar pharmacokinetics of three dosing regimens comprising two oral delayed‐release mesalamine formulations in healthy adult volunteers: Randomised, open‐label, parallel‐group study(2020)5 cited
- → Safety, tolerability, and pharmacokinetics of SMT C1100, a 2‐arylbenzoxazole utrophin modulator, following single‐ and multiple‐dose administration to healthy male adult volunteers(2015)47 cited
- → Pharmacokinetics and Safety of the Selective Progesterone Receptor Modulator Vilaprisan in Chinese Healthy Postmenopausal Women(2020)4 cited
- → Pharmacokinetics of Licarbazepine in Healthy Volunteers: Single and Multiple Oral Doses and Effect of Food(2008)5 cited
- Single- and Multiple-Dose Pharmacokinetics and Tolerability of Limaprost in Healthy Chinese Subjects(2015)